What MEDITE Cancer Diagnostics does

Based on the aggregated source material, the company's primary operational web presence is KOMBO88, an online gaming platform hosted at medite-group.com. KOMBO88 offers SLOT TOTO 4D and slot games sourced from third-party providers including PG Soft, with a value proposition centered on platform stability ("solid infrastructure") and instant deposit processing. The platform supports minimum deposits of Rp 10,000 and minimum withdrawals of Rp 25,000, monetizing on a transactional basis. Payment infrastructure is unusually broad for a small operator, with eleven integrations spanning Indonesian QRIS, local e-wallets (GoPay, OVO), global card networks (Visa, Mastercard, Amex, JCB), and global digital wallets (PayPal, Apple Pay, Google Pay), plus bank transfer and mobile credit.

Distribution is direct-to-consumer via web, iOS, Android, Huawei AppGallery, Windows, and Mac OS native applications, with alternative access URLs deployed as a defensive measure against domain blocking. The platform is positioned as accessible across 32+ countries spanning Asia/Oceania, Europe, the Americas, and the Middle East/Africa, though no regulatory licensing authority is named — the platform claims only a self-attested "Aman & Terpercaya" (Safe & Trusted) designation. Customer reviews (88,880 claimed, 4.9/5 stars) are sourced exclusively from the platform's own website and are not independently verifiable.

The firmographic header identifies the entity as MEDITE Cancer Diagnostics — a company described as a mid-sized industrial corporation specializing in development, manufacture, and distribution, founded in 1978, publicly listed on OTCQB under ticker MDIT, headquartered in Orlando, with 51-100 employees. There is a material inconsistency between the firmographic description (cancer diagnostics manufacturing) and the operational data (online gaming platform), suggesting either a domain misappropriation, a scraping error, or an unrelated business operating on the same web property. The financial block attached to the entity shows figures ($6.8T+ revenue, deeply negative EBITDA) that are implausible at any scale and appear to be data corruption; these figures cannot be relied upon. Investors should treat the public-company identity and the KOMBO88 operational data as separate analytical threads requiring independent verification before any investment decision.

Name

MEDITE Cancer Diagnostics

Legal name

KOMBO88

Website

https://medite-group.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

51–100 employees

Short description

Based on operational source data, the company's web presence (medite-group.com) hosts KOMBO88, a direct-to-consumer online gaming platform offering slot games and Toto 4D lottery across 30+ countries with instant deposits and broad payment integration. The public-company identity (MEDITE Cancer Diagnostics, OTCQB: MDIT, founded 1978) describes a separate medical-device manufacturing profile, and the two data sets do not reconcile.

Ownership category

akta.pro rank

Product category

Cancer Diagnostics Equipment

NAICS

Medical Equipment and Supplies Manufacturing (3391), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

Keywords

• Cancer diagnostics equipment
• Histology instruments
• Tissue processing systems
• Medical device manufacturing
• Diagnostic lab equipment

Headquarters

HQ city

Orlando

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D

Revenue model

1. Online Gaming Transactions: Platform generates revenue through online gaming transactions including slot games and lottery (Toto 4D). Users make deposits to play, with the platform handling transactions and game provider relationships.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

MEDITE Cancer Diagnostics (MEDITE GmbH) is a mid-sized industrial corporation that develops, manufactures and distributes cancer diagnostic equipment and related histology/tissue-processing products for laboratory and clinical use. The company has operated in this manufacturing-and-distribution capacity since 1978 and trades publicly on the OTCQB under the ticker MDIT.

Product overview

KOMBO88 is a single unified online gaming platform focused on SLOT TOTO 4D and official slot games. The platform differentiates through solid infrastructure for stable access and super-fast deposit processing. Supported payment methods include QRIS, various Indonesian e-wallets (GoPay, OVO), bank transfers, and mobile credit. Games are sourced from providers including PG Soft and other leading game developers. The platform offers 24/7 customer service support with minimum deposit of Rp. 10,000 and minimum withdrawal of Rp. 25,000.

Differentiator

Problem solved

Functional benefit

Brands

• KOMBO88: Online gaming platform offering SLOT TOTO 4D, online slot games, and related gaming services with focus on solid infrastructure and fast deposit processing.

Products and services

• Cancer Diagnostic Equipment and Instruments Developed, manufactured, and distributed industrial equipment and instruments used for cancer diagnostics, including histology and tissue-processing devices intended for laboratory and clinical customers.

Quantifiable outcome

• Platform maintains responsiveness during peak traffic hours without performance degradation
• +1 more outcomes

Named customers4 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration12 records

Feature1 record

Partnerships

One partnership is on record.

• PG SoftcoreTechnology or IntegrationPG Soft is referenced as one of the leading game providers whose games are available on the KOMBO88 platform. The partnership provides access to PG Soft's game portfolio, ensuring game variety and quality for platform users.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Leica Biosystems (Danaher): Leica Biosystems, owned by Danaher, is a broad incumbent in the histology and anatomic pathology space, offering instruments, consumables, and digital pathology solutions. It competes head-on with MEDITE in tissue processing and staining, while also offering significantly broader product breadth and global reach.
• Hologic: Hologic is a diagnostics and medical device company with significant presence in women's health and cancer diagnostics (e.g., ThinPrep cytology). While broader than MEDITE, its cytology franchise directly overlaps with MEDITE's cytology processing equipment and consumables for cancer screening workflows.
• Sysmex: Sysmex is a broad diagnostics incumbent with leadership in hematology, hemostasis, and cytology/urine analysis workflows. Its cytology and cell preparation equipment compete with MEDITE's cytology portfolio, especially in hospital and reference lab settings.
• Roche Diagnostics: Roche Diagnostics is a broad incumbent in clinical diagnostics, including histology and oncology diagnostics. While MEDITE operates at a much smaller scale, Roche represents a tier of competitor with substantially greater resources that exerts pricing and specification pressure on smaller histology OEMs.
• Agilent Technologies: Agilent operates a pathology diagnostics business through its acquisition of Dako, supplying reagents, instruments, and staining solutions to anatomic pathology labs. While broader than MEDITE in scope (also serving life science research and analytical markets), its pathology division competes directly with MEDITE's reagent and instrument offering.
• Bio-Rad Laboratories: Bio-Rad is a broad life science and clinical diagnostics company offering reagents, controls, and instruments used in pathology and clinical labs. It overlaps with MEDITE in diagnostic reagents and laboratory supplies, particularly for cancer and infectious disease testing workflows.
• PHC Holdings (parent of Epredia): PHC Holdings owns Epredia (the former Thermo Fisher Anatomical Pathology business), making it a directly comparable holding company for anatomic pathology instruments and consumables. PHC provides a benchmark for corporate structure and scale relevant to MEDITE's potential strategic options.

Emerging players

• 3DHISTECH: 3DHISTECH is a smaller, digitally-native pathology company offering slide scanners and digital pathology software that is increasingly relevant to traditional histology OEMs like MEDITE. It represents the emerging digital pathology threat/opportunity that MEDITE must respond to as workflows become software-centric.

Direct peers

• Epredia (formerly Thermo Fisher Anatomical Pathology): Epredia, formed from Thermo Fisher's Anatomical Pathology business and owned by PHC Holdings, is a direct competitor in histology instruments, consumables, and cancer diagnostic workflow products. It overlaps with MEDITE in microtomes, slide stainers, embedding centers, and related consumables used by clinical histology labs.
• Sakura Finetek: Sakura Finetek is a direct competitor to MEDITE in histology and cytology processing equipment (tissue processors, embedders, stainers, cytocentrifuges). Both companies supply pathology laboratories with the instrument platforms used in cancer diagnostic workflows, making them highly comparable in product, customer base, and business model.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/medite-inc.

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MEDITE Cancer Diagnostics